ICU MEDICAL INC/DE

Listed Company

ICUICIK 0000883984NasdaqLarge AcceleratedSurgical & Medical Instruments & ApparatusDelawareFY ends Dec 31

Period

FY 2025

Revenue

$2.23B

Net Income

$732.0K

Total Assets

$4.05B

Equity

$2.12B

Shares Out

24.99M

Op. Cash Flow

$179.85M

ICUI$154.99+13.92% · past yearDBEQ Basic

Daily closing prices

Business

ICU Medical develops, manufactures and sells medical devices for infusion therapy, vascular access, and vital care applications globally. Its product portfolio spans IV pumps and safety software, infusion sets, catheters, sharps safety products, closed system transfer devices, respiratory and anesthesia equipment, and hemodynamic monitoring systems. The company operates through Consumables (infusion therapy, oncology, vascular access, tracheostomy) and Vital Care (IV solutions distributed via joint venture, hemodynamic monitoring, anesthesia, temperature management) segments. Products are distributed to acute care hospitals, wholesalers, ambulatory clinics and long-term care facilities across over 100 countries.

Summary from 10-K filed 2026-02-19

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenues	2,231	2,382	2,259	2,280	1,316
Cost of Goods Sold	1,409	1,557	1,519	1,582	825
Gross profit	822	825	740	698	491
Selling, general and administrative	625	639	607	608	303
Research and development	87	89	85	93	47
Restructuring, strategic transaction and integration expenses	67	60	41	71	18
Change in fair value of contingent earn-out	0	−5	−16	−32	0
Total operating expenses	779	782	717	741	368
Income from operations	43	43	23	−43	123
Interest Expense, Net	−83	−96	−95	−66	2
OTHER EXPENSE, NET	−232,000	−13	−6	−5	−2
Gain (Loss) on Disposition of Business	45	0	0	—	—
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest, Total	4	−66	−78	—	—
(Provision) benefit for income taxes	−2	−52	49	40	−20
Income (Loss) from Continuing Operations before Equity Method Investments	2	−118	−30	—	—
Income (Loss) from Equity Method Investments	−1	0	0	—	—
Net Income (Loss)	732,000	−118	−30	−74	103
Basic	0.03	−4.83	−1.23	−3.11	4.86
Diluted	0.03	−4.83	−1.23	−3.11	4.74
Basic (in shares)	25	24	24	24	21
Diluted (in shares)	25	24	24	24	22

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation	308	309	254	209	553
Accounts receivable, net of allowance for doubtful accounts of $14,383 at December 31, 2025 and $12,977 at December 31, 2024	181	183	162	222	106
Inventories	616	585	709	696	290
Prepaid expenses and other current assets	86	82	74	89	47
Assets held for sale	0	284	0	—	—
Total current assets	1,191	1,442	1,221	1,235	1,030
PROPERTY, PLANT AND EQUIPMENT, net	452	443	613	636	468
Operating Lease, Right-of-Use Assets	54	53	70	75	40
GOODWILL	1,500	1,433	1,472	1,449	43
INTANGIBLE ASSETS, net	634	741	871	983	188
Deferred Income Tax Assets	26	24	37	31	43
Other Assets	63	65	94	105	64
Equity Method Investments	132	3	—	—	—
TOTAL ASSETS	4,051	4,204	4,378	4,516	1,881
Accounts payable	154	148	150	216	81
Accrued liabilities	315	307	268	243	118
Current portion of long-term debt	19	51	51	30	0
Income tax payable	10	17	8	6	1
Liabilities held for sale	0	33	0	—	—
Total current liabilities	499	556	482	495	201
Long-Term Debt	1,266	1,532	1,578	1,624	0
Other Accrued Liabilities, Noncurrent	90	67	—	—	—
Deferred Income Tax	38	49	56	126	1
Income Tax Liability	35	35	35	42	18
COMMITMENTS AND CONTINGENCIES	0	0	0	0	0
Convertible preferred stock, $1.00 par value Authorized-500 shares; Issued and outstanding - none	0	0	0	0	0
Common stock, $0.10 par value - Authorized-80,000 shares; Issued 24,688 and 24,518 shares at December 31, 2025 and 2024, respectively, and outstanding 24,688 and 24,517 shares at December 31, 2025 and 2024, respectively.	2	2	2	2	2
Additional paid-in capital	1,465	1,412	1,366	1,331	721
Treasury Stock, at cost	−22,000	−92,000	−262,000	−243,000	−27,000
Retained earnings	691	690	808	838	912
Accumulated other comprehensive loss	−35	−139	−53	−81	−19
Total stockholders' equity	2,124	1,965	2,123	2,090	1,616
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	4,051	4,204	4,378	4,516	1,881

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	201	220	229	235	90
Operating Lease, Right-of-Use Asset, Amortization Expense	17	21	22	24	10
Stock compensation	56	47	41	36	27
Loss on Disposition of Property Plant Equipment, net	6	3	2	2	2
Debt issuance cost amortization	6	7	7	7	240,000
Gain (Loss) on Extinguishment of Debt	2	0	0	—	—
Other	24	33	48	−213,000	3
Increase (Decrease) in Accounts Receivable	9	−47	49	−19	14
Increase (Decrease) in Inventories	−26	17	−6	−201	21
Increase (Decrease) in Prepaid Expense and Other Assets	−11	−9	12	23	−8
Increase (Decrease) in Other Operating Assets	−7	−23	−25	−21	−21
Accounts payable	7	13	−68	37	2
Accrued liabilities	−37	21	−14	−56	6
Income taxes, including excess tax benefits and deferred income taxes	−25	26	−82	−67	874,000
Net cash provided by (used in)operating activities	180	204	166	−62	268
Purchases of property, plant and equipment	−88	−79	−84	−90	−69
Proceeds from Divestiture of Businesses	211	0	0	—	—
Proceeds from sale of assets	8	746,000	2	989,000	218,000
Intangible asset additions	−9	−11	−10	−9	−13
Proceeds from sale of investment securities	0	500,000	4	36	18
Net cash used in by investing activities	122	−89	−88	−1,909	−91
Proceeds from issuance of long-term debt, net of lender debt issuance costs	313,000	0	0	1,664	0
Payments of Debt Issuance Costs	−3	0	0	−2	0
Repayments of Long-term obligations	−303	−51	−30	−22	0
Payment of third-party debt issuance costs	2	—	—	—	—
Proceeds from exercise of stock options	6	11	4	9	9
Payments on finance leases	−2	−1	−963,000	−680,000	−607,000
Payment for Contingent Consideration Liability, Financing Activities	0	−3	0	0	−17
Purchase of treasury stock	−9	−12	−9	−11	−8
Net cash (used in) provided by financing activities	−312	−56	−36	1,637	−17
Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation	9	−5	3	−9	−3
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Total	−603,000	54	45	−344	157
Interest Paid, Excluding Capitalized Interest, Operating Activity	84	100	96	64	858,000
Accounts payable for property, plant and equipment	4	7	7	5	9
Direct payoff of a portion of the existing credit facility	−750	—	—	—	—
Transfer to Investments	130	—	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is ICU MEDICAL INC/DE's CIK number?

ICU MEDICAL INC/DE's SEC CIK number is 0000883984 (883984). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find ICU MEDICAL INC/DE's SEC filings?

All of ICU MEDICAL INC/DE's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did ICU MEDICAL INC/DE last report earnings?

ICU MEDICAL INC/DE (ICUI) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0000883984-26-000028). This is ICU MEDICAL INC/DE's most recent earnings filing of record — not a forecast of its next earnings date.

What is ICU MEDICAL INC/DE's most recent earnings 8-K?

ICU MEDICAL INC/DE's latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0000883984-26-000028. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View ICU MEDICAL INC/DE's latest earnings 8-K →
Look up any company's CIK number →